The nervous system has long been recognized as a key player in the regulation of various physiological processes, but its role in cancer biology has only recently begun to be understood. Previous work showed that nerves infiltrate tumors—a process termed neural invasion—correlating tightly with worse patient outcomes. However, the TUM team has now taken this knowledge several steps further by investigating whether cancer cells outside the brain mimic neuronal communication mechanisms to promote their own survival and expansion.

Drawing inspiration from studies conducted approximately six years ago demonstrating that some brain tumors establish synaptic connections with neurons to exploit neurotransmitter signaling, Professor Demir’s team hypothesized that similar synapse-like machinery might be present in tumors located outside the central nervous system. Pancreatic ductal adenocarcinoma, known for its dense innervation and frequent neural invasion, emerged as the prime candidate for such an investigation.

The researchers meticulously examined pancreatic tumor biopsies, focusing on receptor populations known for neurotransmitter binding. They discovered a conspicuous enrichment of N-methyl-D-aspartate (NMDA) receptors—ionotropic glutamate receptors typically involved in excitatory neurotransmission within the brain. This finding was striking, because it suggested the tumors were potentially poised to intercept glutamate signals from surrounding nerve fibers.

To confirm whether these NMDA receptors were part of bona fide synapse-like structures, the team employed electron microscopy, a gold standard technique for ultrastructural analysis. The images revealed distinctive formations bearing resemblance to presynaptic and postsynaptic elements. However, these structures deviated in subtle but critical ways from classical neuronal synapses, prompting the researchers to coin the term “pseudosynapses” to describe these tumor-neuron interfaces.

Functionally, the presence of NMDA receptor-enriched pseudosynapses had profound consequences for pancreatic cancer cell physiology. In normal pancreatic tissue, neuronal glutamate release regulates exocrine and endocrine functions through controlled calcium signaling. The tumor cells co-opt this pathway by allowing glutamate to bind their NMDA receptors, which leads to an influx of calcium ions into the cytoplasm. Unlike transient calcium spikes typical of normal cells, cancer cells exhibit slow and sustained calcium waves that trigger oncogenic signaling cascades, fostering rapid proliferation and enabling metastatic dissemination.

This discovery opens a tantalizing avenue for therapeutic intervention. In preclinical mouse models harboring pancreatic tumors, pharmacological blockade of NMDA receptors markedly slowed tumor growth and metastasis formation. Consequently, treated animals showed a significant extension in survival compared to controls. These findings underscore the clinical potential of targeting neurotransmitter-receptor interactions within the tumor microenvironment, a strategy distinct from conventional cytotoxic or targeted therapies.

Seeking translational relevance, the TUM group is now leveraging advanced bioinformatics approaches to repurpose existing pharmaceuticals. By screening drug libraries for compounds capable of inhibiting NMDA receptors in pancreatic cancer cells, they aim to rapidly progress promising candidates into clinical testing. This strategy not only accelerates drug development timelines but may also help to circumvent the notorious chemoresistance and toxicity issues faced with current treatments.

Beyond pancreatic cancer, the concept of pseudosynapse formation may represent a universal mechanism employed by diverse malignancies to exploit their innervation for growth advantage. The presence of such neuron-cancer communication axes broadens our understanding of tumor biology, shedding light on the complex cross-talk that occurs between the nervous system and cancer cells. This paradigm shift offers an exciting frontier for cancer research and the development of neuromodulatory therapies.

Professor Demir emphasizes the pioneering nature of this discovery, stating, “Our data reveal a previously unrecognized modality through which pancreatic tumors co-opt neuronal signaling to drive their progression. Targeting these neuron-to-tumor connections promises innovative strategies that could transform the bleak outlook faced by pancreatic cancer patients.”

The meticulous work presented in this study exemplifies the power of interdisciplinary research, combining neurobiology, oncology, and advanced imaging to unravel the cellular and molecular interplays underpinning one of the deadliest cancers. It challenges the traditional compartmentalization of cancer as a purely genetic disease by highlighting the crucial influence of physiological systems in shaping tumor behavior.

As the scientific community awaits the clinical translation of these findings, this discovery underscores the importance of investigating the tumor microenvironment beyond cancer cells alone. Interrogating the intricate communication between nerves and tumors may well catalyze a new era in precision oncology wherein the nervous system is recognized as both a regulator and therapeutic target in cancer.

The full results of this compelling investigation have been published in the high-impact journal Cancer Cell, further cementing the significance of this discovery within the oncology research landscape. Additional studies will undoubtedly explore the biochemical details and signaling pathways downstream of NMDA receptor activation in cancer cells, as well as the potential synergistic benefits of combining NMDA receptor blockade with existing therapeutic modalities.

In summary, pancreatic tumors do not merely passively exist within a complex microenvironment; rather, they actively engineer specialized pseudosynaptic junctions to hijack glutamatergic neurotransmission. This fuels calcium-dependent signal transduction pathways that power their malignant growth and dissemination. Blocking these pathways represents a promising frontier in the fight against pancreatic cancer, a disease desperately in need of novel, effective treatment options.

Subject of Research: Animals

Article Title: Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses

News Publication Date: 25-Sep-2025

Web References:
https://www.tum.de/en/news-and-events/all-news/press-releases/details?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews_preview%5D=41479&cHash=8059c50c2351b652a36fac718df7642f

References:
Ren et al., “Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses”, Cancer Cell (2025). DOI: 10.1016/j.ccell.2025.09.003

Keywords: Pancreatic cancer, pseudosynapses, NMDA receptor, glutamate, neural invasion, calcium signaling, tumor microenvironment, neuron-cancer communication, metastasis, translational oncology, targeted therapy, bioinformatics drug repurposing

The multidisciplinary research team employed advanced microscopy techniques to explore the physical and functional nature of contacts between SCLC cells and neurons. Using co-culture systems involving SCLC cells and cortical neurons, investigators applied immunostaining targeting glutamatergic vesicles, specifically using antibodies against vesicular glutamate transporter 1 (VGluT1), and postsynaptic scaffold protein HOMER1. This approach revealed closely juxtaposed puncta indicative of synaptic-like formations directly at the interface of neurons and cancer cells, a phenomenon rarely documented in non-neuronal malignancies.

To ascertain whether these observations extended beyond one experimental model, the researchers utilized human induced pluripotent stem (iPS) cell-derived cortical neurons. These cultures demonstrated consistent synaptic marker colocalization, marked by presynaptic expression of Bassoon in neurons and postsynaptic localization of HOMER1 within SCLC cells. This cross-validation across species and cellular models reinforces the hypothesis of neuron-to-cancer cell synaptic communication.

Further validating the anatomical and physiological relevance of these synapses, the team incorporated mouse nodose ganglia into co-cultures. This peripheral nervous system cluster is known to innervate pulmonary neuroendocrine cells (PNECs), posited as the origin of VGluT1-positive fibers identified in vivo within tumors. Imaging revealed continued juxtaposition of presynaptic VGluT1 and postsynaptic HOMER1 within SCLC cells, confirming that circuits resembling canonical synapses can form under diverse biological contexts.

Transitioning from in vitro systems to in vivo settings, the researchers examined brain allografts containing SCLC cells expressing fluorescent markers. Confocal and electron microscopy analyses identified HOMER1-positive postsynaptic structures in close proximity to axonal boutons labeled by enhanced green fluorescent protein (eGFP), signs of functional synapses. Lung tissue sections from genetically engineered, Cre-exposed RP mice revealed similar contacts at tumor margins, demonstrating that synapse-like interfaces between neurons and cancer cells occur naturally in complex tissue environments.

To achieve nanoscale resolution necessary for definitive structural characterization, the study employed tenfold expansion microscopy (x10ht), attaining spatial resolution near 25 nanometers. Three-dimensional reconstructions of cortical neuron–SCLC co-cultures revealed the spatial organization of presynaptic VGluT1-positive puncta positioned adjacent to postsynaptic HOMER1 immunoreactivity in cancer cells. This spatial fidelity is consistent with the nanometer-scale architecture of classical excitatory synapses in the central nervous system.

To push resolution boundaries further, the investigators applied one-step nanoscale expansion (ONE) microscopy, a super-resolution technique affording even finer visualization of synaptic components. Both three-dimensional and two-dimensional imaging modalities highlighted clear segregation of pre- and postsynaptic elements. Quantitative measurements revealed that the physical distance between VGluT1 and HOMER1 puncta at neuron–cancer cell contacts mirrored that observed at established neuron–neuron synapses within the same cultures, strengthening the assertion of synaptic conformity.

Correlative light and electron microscopy (CLEM), integrating high-resolution fluorescence imaging with ultrastructural analysis, constituted a pivotal validation strategy. Electron tomograms of fluorescently labeled SCLC cells in brain allografts revealed presynaptic boutons densely packed with synaptic vesicles in direct contact with cancer cell membranes. The presence of clearly defined synaptic clefts and vesicle pools within 20 nanometers from the presynaptic membrane echoed canonical synapse ultrastructure, affirming the authenticity of these specialized cell junctions.

A systematic examination of 280 cell perimeters at the periphery of the cancer allografts indicated that approximately 8.2% of SCLC cells formed synapses with axonal boutons, a substantial proportion given the heterogeneity of tumor microenvironments. This prevalence underscores the biological significance of these synaptic interactions and suggests potential roles in tumor progression, neuro-immune modulation, or therapeutic resistance mechanisms.

The discovery of synaptic connections between neural axons and SCLC cells challenges the traditional view of tumor biology as an exclusively cell-autonomous process, highlighting instead a dynamic neuro-cancer interface that may influence cancer cell behavior. Such functional synapses could mediate bidirectional communication, enabling neurons to modulate cancer cell signaling pathways and, reciprocally, cancer cells to influence neuronal circuitry.

Beyond structural characterization, these findings prompt intriguing questions regarding the nature of synaptic transmission between neurons and SCLC cells. Functional assays addressing whether neurotransmitter release at these synapses affects cancer proliferation, survival, or metastatic potential could expand understanding of how neuronal inputs integrate into tumor biology.

Moreover, this research paves the way for exploring synaptic-targeted therapies in oncology. Drugs disrupting synaptic machinery or modulating glutamatergic signaling might impair tumor growth or sensitize cancer cells to existing treatments. Given the critical role of synaptic proteins like VGluT1 and HOMER1 in these interfaces, they emerge as promising biomolecular targets for drug development.

The technological innovations applied, combining expansion microscopy with super-resolution and CLEM, exemplify state-of-the-art approaches to dissecting tumor microenvironments at near-molecular resolution. Such methodologies can be heralded as essential tools for future investigations into other cancer types and their interactions with the nervous system.

This seminal study offers a paradigm shift, revealing that SCLC cells can integrate into neural networks through bona fide synapses, thereby participating in complex cellular dialogues previously unappreciated in cancer research. As neuroscience and oncology converge, the characterization of tumor–neuron synapses heralds a new frontier with profound implications for cancer biology and therapeutic strategy.

Subject of Research: Synaptic interactions between neurons and small cell lung cancer cells.

Article Title: Functional synapses between neurons and small cell lung cancer.

Article References: Sakthivelu, V., Schmitt, A., Odenthal, F. et al. Functional synapses between neurons and small cell lung cancer. Nature (2025). https://doi.org/10.1038/s41586-025-09434-9

Image Credits: AI Generated

Recent groundbreaking research has unveiled a startling connection between small cell lung cancer (SCLC) and the nervous system, revealing that malignant cells actively form synaptic connections with neurons within the brain’s microenvironment. This discovery uncovers a sophisticated neural-cancer communication pathway that might be driving tumor growth and resistance, reshaping our understanding of cancer biology and opening new therapeutic avenues.

For years, the interactions between cancer cells and the nervous system remained an underexplored frontier. The conventional view held that cancer cells proliferate largely independent of direct neuronal influence. However, new evidence now identifies that SCLC cells not only interact structurally with neurons but integrate into neural circuits via bona fide synapses, the specialized junctions through which neurons communicate electrically and chemically.

Using electron microscopy, investigators visualized synaptic contacts where GFP-labelled SCLC cells occupied post-synaptic positions opposite presynaptic terminals of neurons in various brain graft models. This synaptic architecture was characterized by classic features: electron-dense post-synaptic densities, organized synaptic vesicles in apposing neurons, and clearly defined synaptic clefts. Immunogold labeling targeting the GFP tag effectively demarcated tumor cells as true postsynaptic partners, with an estimated frequency of three to five synapses per ten cancer cells. Intriguingly, tumor cells were also observed in a perisynaptic stance adjacent to endogenous neuron–neuron synapses, analogous to ‘pseudo-tripartite’ synapses previously described in other metastatic cancers, indicating complex integrative interactions within neural networks.

Beyond the ultrastructural validation of these neuron-to-cancer synapses, electrophysiological recordings have demonstrated functional synaptic transmission onto SCLC cells. Whole-cell voltage-clamp recordings from individual GFP-labelled tumor cells implanted inside the hippocampal CA1 region—a prime, experimentally accessible neural circuit—revealed spontaneous excitatory postsynaptic currents (sEPSCs) in approximately one-fifth of the examined cancer cells. These spontaneous currents were abolished upon application of NBQX, a selective antagonist of AMPA-type glutamate receptors, confirming that SCLC cells receive glutamatergic synaptic input. This indicates that malignant cells possess active receptors capable of detecting and responding to excitatory neurotransmitter release.

To probe responsiveness to action potential-driven neuronal activity, researchers electrically stimulated the Schaffer collateral axons—inputs to CA1 neurons—while recording tumor cells at defined membrane potentials. When held at −70 mV, SCLC cells demonstrated minimal evoked responses. However, depolarizing the cells to 0 mV, which dampens glutamatergic currents, unmasked large currents in a majority of cells that were eliminated by tetrodotoxin (TTX), a blocker of neuronal action potentials. The pharmacological dissection of these evoked responses revealed they were mediated by GABAergic inputs, as their blockade by gabazine, a GABA_A receptor antagonist, eliminated the synaptic currents. These findings collectively reveal that SCLC cells receive inhibitory, but paradoxically depolarizing, GABAergic synaptic input.

Decoding the paradox required meticulous measurement of intracellular chloride concentrations in these malignant cells. Employing perforated-patch electrophysiology with gramicidin D—preserving native intracellular ion gradients—the investigators determined a GABA reversal potential around −27 mV, which is significantly depolarized compared to the resting membrane potential of −72 mV measured by cell-attached recordings. This unusual chloride gradient is driven by overexpression of the NKCC1 co-transporter relative to KCC2, disrupting chloride homeostasis in cancer cells. Consequently, activation of GABA_A channels results in chloride efflux and membrane depolarization, functionally rendering inhibitory neurotransmission excitatory within SCLC.

This depolarizing effect of neurotransmitters on SCLC cells has important implications. Classically associated with neural excitability and plasticity, depolarization may influence intracellular signaling cascades promoting tumor cell proliferation and survival. Indeed, co-culture experiments involving SCLC cells and human iPSC-derived glutamatergic or GABAergic neurons have demonstrated enhanced tumor cell proliferation. Pharmacological blockade of NMDA and AMPA glutamate receptors or GABA_A receptors significantly abrogated this increased proliferative index, emphasizing that the functional synaptic signaling from neurons facilitates cancer progression.

These findings collectively redefine the tumor microenvironment in brain metastases of SCLC, establishing the malignant cells as synaptic partners within neural circuits. The identification of neuron-to-cancer synaptic interactions illustrates an active dialogue where neurons not only coexist with tumor cells but may directly drive tumorigenesis through neurotransmitter-mediated membrane depolarization and signaling pathways.

This novel understanding of cancer-neuron synapses prompts a paradigm shift in targeting SCLC and possibly other cancers with neural involvement. Therapeutic strategies could evolve to disrupt synaptic connectivity or modulate neurotransmitter receptor function on tumor cells, ultimately impeding the neuronal facilitation of cancer progression. By intervening in this neural-cancer crosstalk, it might be possible to curb tumor growth or enhance responses to conventional treatments.

Moreover, this work highlights the importance of the brain’s unique biochemical milieu in shaping cancer behavior. The aberrant chloride gradient and depolarizing GABAergic signaling in tumor cells represent a previously unappreciated form of neurochemical adaptation, underscoring the metabolic and functional plasticity of malignant cells within the nervous system.

Future research directions are manifold. Illuminating the molecular mechanisms downstream of neurotransmitter receptor activation in SCLC cells could reveal new oncogenic pathways. Investigating whether other tumor types establish similar synaptic contacts could broaden the impact of these discoveries. Ultimately, understanding how neuronal activity influences tumor initiation, invasion, and therapeutic resistance could revolutionize neuro-oncology.

In sum, this remarkable study exposes a hidden neural circuit within brain tumors, where SCLC cells have appropriated synaptic machinery to hijack neuronal signals for their malignant advantage. By bridging cancer biology and neurophysiology, it opens a compelling new chapter of interdisciplinary research with immense potential to transform cancer treatment paradigms.

Subject of Research: Neuronal activity-dependent mechanisms in the pathogenesis of small cell lung cancer.

Article Title: Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis.

Article References:
Savchuk, S., Gentry, K.M., Wang, W. et al. Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis. Nature (2025). https://doi.org/10.1038/s41586-025-09492-z

Image Credits: AI Generated